BioMed Research International / 2016 / Article / Tab 6

Research Article

Association between the Achievement of Target Range CKD-MBD Markers and Mortality in Prevalent Hemodialysis Patients in Taiwan by Using the Kidney Disease: Improving Global Outcomes Clinical Guidelines

Table 6

Odds ratio of all-cause and CV mortality by achievement of KDIGO clinical guideline.

  OR (95% CI)
Model 1Model 2Model 3

All-cause
All1.001.001.00
Ca + P1.52 (1.05~2.21)0.021.85 (1.16~2.95)0.0091.66 (1.01~2.73)0.04
Ca + iPTH0.96 (0.60~1.52)0.841.39 (0.81~2.39)0.231.43 (0.77~2.68)0.25
P + iPTH1.07 (0.46~2.52)0.871.50 (0.59~3.78)0.391.32 (0.46~3.77)0.60
Ca1.85 (1.14~3.00)0.014.02 (2.12~7.63)<0.0013.16 (1.52~6.59)0.002
P3.95 (1.65~9.46)0.0024.54 (1.61~12.8)0.0043.55 (1.05~12.0)0.04
iPTH2.51 (1.08~5.83)0.034.69 (1.56~14.1)0.0054.70 (1.44~15.4)0.01
None2.19 (1.06~4.52)0.031.99 (0.77~5.13)0.153.91 (1.00~15.3)0.05

CV
All1.001.001.00
Ca + P1.30 (0.60~2.85)0.501.30 (0.49~3.41)0.591.39 (0.51~3.77)0.51
Ca + iPTH1.75 (0.78~3.92)0.172.58 (1.04~6.39)0.042.96 (1.08~8.13)0.03
P + iPTH0.77 (0.10~5.96)0.801.40 (0.17~11.9)0.751.01 (0.11~9.66)0.99
Ca1.39 (0.50~3.89)0.524.13 (1.32~13.0)0.014.35 (1.20~15.9)0.02
PNANANA
iPTH3.71 (1.01~13.6)0.043.47 (0.62~19.4)0.152.40 (0.40~14.3)0.33
None1.58 (0.35~7.14)0.550.82 (0.10~6.86)0.851.43 (0.12~16.9)0.77

Logistic regression model:
Model 1: unadjusted.
Model 2: adjusted for age, sex, hemodialysis vintage, etiology of renal failure, EPO, vitamin-D analogs, antihypertensive agent, iron use, and parathyroidectomy.
Model 3: model 2 + baseline laboratory results (albumin, hemoglobin, cholesterol, triglyceride, glucose (fasting), ferritin, Ca, P, iPTH, potassium, uric acid, urea, and cardiac-thoracic ratio).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.